Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2015
Price :
$35
*
At a glance
- Drugs Toludesvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 17 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2014 New trial record